Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis

NCT05034822 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05034822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05034822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
December 16, 2021
Completion date
August 7, 2023
Enrollment
29 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis